KLS-13019 is a highly effective and orally active GPR55 receptor antagonist, a cannabidiol (CBD)-derived neuroprotective agent that can reverse chemotherapy-induced peripheral neuropathy (CIPN) and is suitable for studying hepatic encephalopathy (HE).
Molecular Weight:
355.47
Purity:
>99.99%
CAS Number:
[1801243-39-9]
Formula:
C22H29NO3
Target:
Cannabinoid Receptor
T32402
* VAT and and shipping costs not included. Errors and price changes excepted